Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mimi I Hu

Showing results (41-50 of 92) with videos related to

Pageof 10
Sort By:
The Journal of Clinical Endocrinology and Metabolism|December 22, 2022
Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice GuidelineGhada El-Hajj Fuleihan, Gregory A Clines, Mimi I Hu, et al.
Thyroid : Official Journal of the American Thyroid Association|August 23, 2018
Immune-Related Thyroiditis with Immune Checkpoint InhibitorsPriyanka C Iyer, Maria E Cabanillas, Steven G Waguespack, et al.
Endocrine-Related Cancer|June 25, 2020
HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: The state of science in medullary thyroid carcinoma: current challenges and unmet needsRamona Dadu, Rozita Bagheri-Yarmand, Matthew D Ringel, et al.
Endocrinology, Diabetes & Metabolism|March 1, 2019
Gender differences in bone mineral density in patients with sporadic primary hyperparathyroidismDanica M Vodopivec, Angelica M Silva, Dinamarie C Garcia-Banigan, et al.
Cell Reports. Medicine|December 20, 2023
Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancersMirella Nardo, Mohamed A Gouda, Blessie E Nelson, et al.
Future Oncology (London, England)|August 15, 2022
LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve <i>RET</i>-mutant medullary thyroid cancerLori J Wirth, Marcia S Brose, Rossella Elisei, et al.
Thyroid : Official Journal of the American Thyroid Association|December 4, 2024
Efficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid CarcinomaSarah Hamidi, Sireesha Yedururi, Mimi I Hu, et al.
The Oncologist|April 16, 2014
Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancerRamona Dadu, Steven G Waguespack, Steven I Sherman, et al.
Familial Cancer|November 20, 2016
All in the family? Analyzing the impact of family history in addition to genotype on medullary thyroid carcinoma aggressiveness in MEN2A patientsKristin L Long, Carol Etzel, Thereasa Rich, et al.
The Journal of Clinical Endocrinology and Metabolism|October 30, 2014
Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experienceRamona Dadu, Komal Shah, Naifa L Busaidy, et al.
Pageof 10

Showing results (41-50 of 92) with videos related to

Sort By:
Pageof 10
The Journal of Clinical Endocrinology and Metabolism|December 22, 2022
Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice GuidelineGhada El-Hajj Fuleihan, Gregory A Clines, Mimi I Hu, et al.
Thyroid : Official Journal of the American Thyroid Association|August 23, 2018
Immune-Related Thyroiditis with Immune Checkpoint InhibitorsPriyanka C Iyer, Maria E Cabanillas, Steven G Waguespack, et al.
Endocrine-Related Cancer|June 25, 2020
HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: The state of science in medullary thyroid carcinoma: current challenges and unmet needsRamona Dadu, Rozita Bagheri-Yarmand, Matthew D Ringel, et al.
Endocrinology, Diabetes & Metabolism|March 1, 2019
Gender differences in bone mineral density in patients with sporadic primary hyperparathyroidismDanica M Vodopivec, Angelica M Silva, Dinamarie C Garcia-Banigan, et al.
Cell Reports. Medicine|December 20, 2023
Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancersMirella Nardo, Mohamed A Gouda, Blessie E Nelson, et al.
Future Oncology (London, England)|August 15, 2022
LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve <i>RET</i>-mutant medullary thyroid cancerLori J Wirth, Marcia S Brose, Rossella Elisei, et al.
Thyroid : Official Journal of the American Thyroid Association|December 4, 2024
Efficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid CarcinomaSarah Hamidi, Sireesha Yedururi, Mimi I Hu, et al.
The Oncologist|April 16, 2014
Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancerRamona Dadu, Steven G Waguespack, Steven I Sherman, et al.
Familial Cancer|November 20, 2016
All in the family? Analyzing the impact of family history in addition to genotype on medullary thyroid carcinoma aggressiveness in MEN2A patientsKristin L Long, Carol Etzel, Thereasa Rich, et al.
The Journal of Clinical Endocrinology and Metabolism|October 30, 2014
Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experienceRamona Dadu, Komal Shah, Naifa L Busaidy, et al.
Pageof 10